{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-078823","form_type":"8-K","ticker":"NVCT","cik":"0001875558","company_name":"Nuvectis Pharma, Inc.","filed_at":"2026-06-29T20:07:30+00:00","discovered_at":"2026-06-29T20:09:00.288824+00:00","generated_at":"2026-06-29T20:09:25.631907+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"medium","headline":"Nuvectis Pharma reduces ATM capacity to $5M and suspends sales under Leerink agreement","bullets":["On June 29, 2026, Nuvectis lowered the amount available for sale under the Sales Agreement Prospectus to $5 million.","The company is suspending the Sales Agreement Prospectus and will not sell any shares until a new prospectus or registration statement is filed.","The Sales Agreement with Leerink Partners LLC remains in full force and effect; only the current offering is paused."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-078823","json":"https://secwatch.observer/filing/0001104659-26-078823.json","markdown":"https://secwatch.observer/filing/0001104659-26-078823.md","text":"https://secwatch.observer/filing/0001104659-26-078823.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1875558/000110465926078823/0001104659-26-078823-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1875558/000110465926078823/tm2618981d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T20:09:25.631907+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}